Dimitrios Colevas

748 total citations
27 papers, 571 citations indexed

About

Dimitrios Colevas is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dimitrios Colevas has authored 27 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dimitrios Colevas's work include Cancer Treatment and Pharmacology (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (5 papers). Dimitrios Colevas is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (5 papers). Dimitrios Colevas collaborates with scholars based in United States, France and Germany. Dimitrios Colevas's co-authors include Sanjay Goel, Sridhar Mani, Mace L. Rothenberg, Dominik Verdier-Pinard, Tito Fojo, Mark Morrow, M. Basche, Anna E. Barón, Darren W. Davis and Scott N. Holden and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dimitrios Colevas

27 papers receiving 555 citations

Peers

Countries citing papers authored by Dimitrios Colevas

Since Specialization

Citations

This map shows the geographic impact of Dimitrios Colevas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dimitrios Colevas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dimitrios Colevas more than expected).

Fields of papers citing papers by Dimitrios Colevas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dimitrios Colevas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dimitrios Colevas. The network helps show where Dimitrios Colevas may publish in the future.

Co-authorship network of co-authors of Dimitrios Colevas

This figure shows the co-authorship network connecting the top 25 collaborators of Dimitrios Colevas. A scholar is included among the top collaborators of Dimitrios Colevas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dimitrios Colevas. Dimitrios Colevas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial 2021 ·Annals of Oncology ·Dimitrios Colevas, Krzysztof Misiukiewicz, Alexander T. Pearson, Jérôme Fayette, Jessica R. Bauman, Didier Cupissol, Esma Saâda-Bouzid, Douglas R. Adkins, (unknown), Stéphanie Cornen, Pascale André, Florent Carrette, Federico Rotolo, (unknown), Romain Cohen	12
2	20 Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy 2021 ·SHILAP Revista de lepidopterología ·Charles W. Abbott, (unknown), Jing Wang, Josette Northcott, Rachel Marty Pyke, Robin Li, Lee McDaniel, Éric Levy, Mena Mansour, Dimitrios Colevas, John Lyle, John B. Sunwoo, Seán Boyle, Richard Chen	1
3	81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial 2020 ·Annals of Oncology ·Jérôme Fayette, Jessica R. Bauman, Sébastien Salas, Dimitrios Colevas, Caroline Even, Didier Cupissol, Marshall R. Posner, G. Lefebvre, Esma Saâda-Bouzid, (unknown), Tanguy Y. Seiwert, Alexander T. Pearson, (unknown), Stéphanie Cornen, Paúl André, Federico Rotolo, Agnès Boyer-Chammard, Roger B. Cohen	3
4	Intraoperative Tumor Assessment Using Real-Time Molecular Imaging in Head and Neck Cancer Patients 2019 ·Journal of the American College of Surgeons ·Stan van Keulen, Naoki Nishio, Shayan Fakurnejad, Nynke S. van den Berg, Guolan Lu, Andrew C. Birkeland, Brock A. Martin, Tymour Forouzanfar, Dimitrios Colevas, Eben L. Rosenthal	32
5	Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data 2019 ·Annals of Oncology ·Romain Cohen, G. Lefebvre, Marshall R. Posner, Jessica R. Bauman, Sébastien Salas, Caroline Even, Esma Saâda-Bouzid, Tanguy Y. Seiwert, Dimitrios Colevas, (unknown), Robert Zerbib, Pascale André, Agnès Boyer-Chammard, Jérôme Fayette	16
6	Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy 2018 ·Cancer Research ·Roger B. Cohen, Jérôme Fayette, Marshall R. Posner, G. Lefebvre, Jessica R. Bauman, Sébastien Salas, Caroline Even, Tanguy Y. Seiwert, Dimitrios Colevas, Antonio Jimeno, Esma Saâda, Barbara Burtness, Pascale André, Carine Paturel, Cécile Bonnafous, (unknown), (unknown), Robert Zerbib, Agnès Boyer-Chammard	10
7	Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics 2015 ·Proceedings of the IEEE ·Savaş Taşoğlu, H. Cumhur Tekin, Fatih İnci, Stephanie Knowlton, (unknown), Feng Wang‐Johanning, Gary L. Johanning, Dimitrios Colevas, Utkan Demirci	34
8	Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. 2013 ·Molecular Cancer Therapeutics ·Antonio Jimeno, Thomas J. Galloway, Lori J. Wirth, Jill Gilbert, Nabil F. Saba, Julie E. Bauman, Dimitrios Colevas, Ranee Mehra, David Raben, Cheng-Jung Lai, Robert J Laliberte, Maurizio Voi, Barbara Burtness	1
9	Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Hongbin Cao, Alice Banh, Shirley Kwok, Xiaoli Shi, (unknown), (unknown), Brian Khong, (unknown), (unknown), Benjamin A. Pinsky, Dimitrios Colevas, Nader Pourmand, Albert C. Koong, Christina S. Kong, Quynh‐Thu Le	96
10	A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma 2007 ·Cancer Biology & Therapy ·Edwin M. Posadas, Samir D. Undevia, (unknown), James L. Wade, Dimitrios Colevas, Theodore Karrison, Everett E. Vokes, Walter M. Stadler	18
11	Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors 2007 ·Annals of Oncology ·Seetharaman Hariharan, Daniel L. Gustafson, Scott N. Holden, David J. McConkey, Darren W. Davis, Mark Morrow, M. Basche, Lia Gore, C. Zang, (unknown), Anna E. Barón, (unknown), Dimitrios Colevas, Sabine Eckhardt	97
12	University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC) 2007 ·Journal of Clinical Oncology ·(unknown), (unknown), Dimitrios Colevas, Nancy B. Davis, Joseph I. Clark, Edem Agamah, Sachdev Thomas, (unknown), Bruce G. Redman, Walter M. Stadler	6
13	Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone 2006 ·Annals of Oncology ·Sridhar Mani, (unknown), Ashley Grossman, Franco M. Muggia, Sanjay Goel, T. Griffin, Dimitrios Colevas, (unknown), (unknown)	14
14	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity. 2006 ·Blood ·Thomas S. Lin, Mitch A. Phelps, James T. Dalton, Beth Fischer, Kristie A. Blum, Mollie E. Moran, (unknown), (unknown), Dimitrios Colevas, John C. Byrd, Michael R. Grever	4
15	Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design 2005 ·Clinical Cancer Research ·Shirish M. Gadgeel, Antoinette J. Wozniak, Ramesh Boinpally, Richard Wiegand, Lance K. Heilbrun, Vikas Jain, Ralph E. Parchment, Dimitrios Colevas, Marvin B. Cohen, Patricia LoRusso	59
16	The clinical development of new mitotic inhibitors that stabilize the microtubule 2004 ·Anti-Cancer Drugs ·Sridhar Mani, (unknown), Sanjay Goel, Dominik Verdier-Pinard, Tito Fojo, Mace L. Rothenberg, Dimitrios Colevas	55
17	A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F) 2004 ·Journal of Clinical Oncology ·(unknown), Jeremy Kortmansky, Mithat Gönen, Archie Tse, Robert A. Lefkowitz, David P. Kelsen, Dimitrios Colevas, (unknown), Yi Shi, Gary N. Schwartz	10
18	A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM) 2004 ·Journal of Clinical Oncology ·Anne C. Pavlick, Michael Millward, Kathleen Farrell, A. Hamilton, (unknown), Naomi B. Haas, Tsiporah B. Shore, (unknown), Dimitrios Colevas, Franco M. Muggia	21
19	Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111) 2004 ·Journal of Clinical Oncology ·Maha Hussain, James R. Faulkner, Ulka N. Vaishampayan, Primo N. Lara, Daniel P. Petrylak, Dimitrios Colevas, Wael Sakr, E. David Crawford	14
20	Clinical trials referral resource. Flavopiridol. 2002 ·PubMed ·Dimitrios Colevas, Barbara Blaylock, Amy Gravell	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact